Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
FiercePharma

Sanofi, Regeneron launch new Dupixent asthma TV ad urging patients to 'Du More' water sliding

The long-running “Du More” motif for Sanofi and Regeneron’s immunology blockbuster Dupixent is looking to make a splash with its first new commercial of 2023. In the 60-second spot, “It's Possible: ...
InvestorsHub on MSN

Regeneron (REGN) Dupixent phase 4 trial results show improved esophageal function in EoE

New clinical data reinforce Dupixent’s role in treating eosinophilic esophagitis and may support its long-term positioning in ...
Business Insider

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU ...
Nasdaq

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...
Seeking Alpha

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...
Seeking Alpha

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
WebMD

Dupixent: FDA Approves First and Only Medicine for Allergic Fungal Rhinosinusitis in Adults and Children Ages 6 Years and Older

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...